Elobixibat Hydrate: Selective IBAT Inhibitor for Constipation

Executive Summary: Elobixibat hydrate acts by selectively inhibiting the ileal bile acid transporter (IBAT), increasing colonic bile acid concentrations and promoting enhanced bowel motility (source: product_spec). The compound demonstrates low systemic bioavailability, with plasma levels in the picomolar range and a protein binding rate exceeding 99% (source: product_spec). Clinically, elobixibat hydrate improves spontaneous bowel movements and stool consistency, lowers LDL cholesterol by 21.4 mg/dL, and modestly reduces HbA1c by approximately 0.2% in patients with type 2 diabetes mellitus (source: product_spec). Adverse events are generally mild to moderate, with a favorable safety profile (source: product_spec). The compound is supplied by APExBIO as SKU C8720 for research and clinical integration.

Biological Rationale

Bile acids are critical regulators of intestinal function and metabolic homeostasis. Reabsorption of bile acids in the terminal ileum is mediated by the ileal bile acid transporter (IBAT, also known as SLC10A2). Inhibition of IBAT disrupts enterohepatic circulation, increasing luminal bile acid concentrations in the colon. This leads to activation of the G protein-coupled bile acid receptor TGR5, which stimulates secretion of glucagon-like peptide-1 (GLP-1) and enhances colonic motility (source: miglitol_article). Increased GLP-1 also improves glucose metabolism and lipid profiles. This mechanism provides the rationale for using IBAT inhibitors such as elobixibat hydrate in chronic idiopathic constipation and metabolic disorders.

Mechanism of Action of Elobixibat hydrate

Elobixibat hydrate (CAS No. 1633824-78-8) is a highly selective IBAT inhibitor that binds to and blocks bile acid reabsorption in the ileal mucosa (source: product_spec). As a result, more bile acids reach the colon, where they activate TGR5 on enteroendocrine cells, promoting GLP-1 release and increasing water and electrolyte secretion into the bowel lumen. This leads to accelerated intestinal transit and improved bowel function (source: tenapanorchem_article). The increased GLP-1 also contributes to improved glycemic control and reduction of LDL cholesterol. Elobixibat hydrate exhibits >99% plasma protein binding and a half-life of less than 4 hours, minimizing systemic exposure (source: product_spec).

Evidence & Benchmarks

• Oral administration of 10 mg elobixibat hydrate once daily increases spontaneous bowel movements in patients with chronic idiopathic constipation (source: product_spec).
• Elobixibat improves stool consistency and frequency, with onset of action typically within 24 hours (source: miglitol_article).
• A single 10 mg dose is effective as bowel preparation prior to colonoscopy, enhancing colonic cleansing (source: tenapanorchem_article).
• HbA1c is reduced by approximately 0.2% in patients with type 2 diabetes mellitus following regular elobixibat use (source: product_spec).
• LDL cholesterol is lowered by 21.4 mg/dL on average after elobixibat therapy (source: product_spec).
• Plasma concentrations are in the picomolar range due to low systemic absorption, reducing risk of off-target effects (source: product_spec).
• Protein binding exceeds 99%, and the elimination half-life is less than 4 hours (source: product_spec).
• Adverse effects are mainly gastrointestinal (abdominal pain, distension, diarrhea) and are typically mild to moderate (source: product_spec).

Applications, Limits & Misconceptions

Elobixibat hydrate is primarily approved for the treatment of chronic idiopathic constipation, for pre-colonoscopy bowel preparation, and for ameliorating metabolic abnormalities in type 2 diabetes mellitus (source: tenapanormed_article). Its use is expanding in research settings to study bile acid physiology and gut-liver axis modulation. The product is not indicated for hereditary angioedema or for acute management of other gastrointestinal emergencies (source: DOI:10.18176/jiaci.0653). While elobixibat hydrate demonstrates robust efficacy in constipation and metabolic modulation, it is not suitable for patients with known bile acid malabsorption disorders or severe hepatic impairment (workflow_recommendation).

This article extends the findings in Elobixibat Hydrate: Selective IBAT Inhibitor for Constipation (miglitol.com) by providing structured evidence, protocol parameters, and explicit clinical boundaries for research and translational use.

For advanced mechanistic insights, see Elobixibat hydrate: Selective IBAT Inhibitor for Constipation (tenapanorchem.com), which offers workflow troubleshooting and comparative application notes—this article clarifies approved clinical endpoints and product handling.

For a molecular perspective, Elobixibat hydrate: Beyond Constipation—A Molecular Perspective (tenapanormed.com) explores emerging research; here, clinical scope and limitations are highlighted.

Common Pitfalls or Misconceptions

• Elobixibat hydrate is not a universal laxative; its efficacy is limited to conditions driven by reduced bile acid-dependent colonic motility.
• It should not be used in patients with severe hepatic dysfunction or known bile acid malabsorption syndromes (workflow_recommendation).
• No evidence supports its use in hereditary angioedema or in modulating the kallikrein-kinin pathway (source: DOI:10.18176/jiaci.0653).
• Elobixibat hydrate is insoluble in water and requires DMSO or ethanol (with sonication) for laboratory use (source: product_spec).
• It is not intended for acute treatment of gastrointestinal obstruction or for pediatric populations without further evidence (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• cell viability assay | 10 μM in DMSO | in vitro, colon epithelial cells | standard concentration for screening IBAT inhibition | workflow_recommendation
• animal model, oral dosing | 10 mg/kg/day | mouse/rat, chronic constipation models | matches clinical dosing for translational relevance | product_spec
• clinical bowel prep | 10 mg single dose, oral | adult human, colonoscopy prep | maximizes colonic bile acid for cleansing | product_spec
• storage | 4°C, sealed dry | all applications | maintains compound integrity | product_spec
• solubility | ≥49.2 mg/mL in DMSO; ≥9.82 mg/mL in ethanol (with sonication) | stock solution preparation | enables accurate dosing in preclinical and screening workflows | product_spec

Conclusion & Outlook

Elobixibat hydrate, as supplied by APExBIO (SKU C8720), is a validated, selective IBAT inhibitor that reliably improves chronic idiopathic constipation, supports bowel preparation, and yields favorable metabolic effects in type 2 diabetes mellitus (source: product_spec). Its favorable safety, low systemic bioavailability, and well-characterized mechanism underpin broad utility in both research and clinical settings. Future work aims to optimize patient selection and expand the mechanistic understanding within approved indications, as highlighted in recent structured reviews (source: miglitol_article). No evidence currently supports use in unrelated inflammatory or angioedema contexts.